Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal Phase 3 clinical trial assessing GP-2250 as a first-line maintenance therapy for pancreatic cancer in non-BRCA mutation patients

Next Previous
Trial Profile

A pivotal Phase 3 clinical trial assessing GP-2250 as a first-line maintenance therapy for pancreatic cancer in non-BRCA mutation patients

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Misetionamide (Primary)
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Panavance Therapeutics

Most Recent Events

  • 20 Mar 2023 According to Panavance Therapeutics media release, this study is expected to start in early 2024
  • 13 Aug 2022 New trial record
  • 08 Aug 2022 According to Panavance therapeutics media release, this trial will initiate in H2 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top